Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2022.

BGI Genomics released the 2022 annual fiscal forecast. The operating revenue is expected to reach CNY 6.4 to 7.4 billion; the net profit attributable to shareholders of the listed companies is forecast to be CNY 800 million to 1.04 billion.

Siemens Healthineers AG today announces its results for the first quarter of fiscal year 2023, ending December 31, 2022.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal 2023, which ended December 31, 2022.

On January 30, Forbes China revealed its list of emerging unicorns in China for 2022. Forbes China tracked more than 2,000 startups that raised more than RMB 200 million or USD 30 million in a single round of funding in the past year and are likely to cross over into the unicorn category.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022.

Roche Diagnostics plans to bring a fully automated mass spectrometry-based clinical analyzer to market in 2024.

After three years, China announced its reopening from January 8, 2023. Passengers can enter China without quarantine. All you need is a negative PCR result within 48 hours before departure. You do not need to apply for a health code.

Beckman Coulter Diagnostics announced on Tuesday that it has entered a strategic partnership with Israeli diagnostic company MeMed to develop and commercialize a host immune response diagnostic test.

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2022.

On January 31, A-share listed Daan Gene released the 2022 full-year performance forecast.

Precision oncology company Guardant Health announced on Monday that FDA has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic.

SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2022.

Easy Diagnosis released a performance preview on the evening of January 30, expecting 2022 net profit attributable to shareholders of listed companies of CNY4.6 billion to CNY5 billion, an increase of 225.5% to 253.8%; basic earnings per share of about CNY29.99 to CNY32.60.

GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, reported financial results for the fourth quarter and full year ended December 31, 2022.